Genmab — Juli 2022
-
the Japanese Epcoritamab trial starts recruiting again, with a few additional arms added https://www.clinicaltrials.gov/ct2/history/NCT04542824?A=5&B=6&C=merged#StudyPageTop
-
Akter/middag: Bavarian rykker på godkendelse - banker kommer lidt igen https://www.proinvestor.com/investornyt/854869/akter-middag-bavarian-rykker-pa-godkendelse-banker-kommer-lidt-igen
-
Ofatumumab forbedrer RMS-patienters kognition https://mstidsskrift.dk/37-sygdom/767-ofatumumab-forbedrer-rms-patienters-kognition.html
-
"Medicinske tidsskrifter har tidligere beskrevet, hvorvidt studiet har konkluderet, at ofatumumab viser en bedre effekt på attakker og disability end teriflunomid".
-
Tak Bulder.

-
Transactions in connection with share buy-back program https://www.proinvestor.com/investornyt/854921/transactions-in-connection-with-share-buy-back-program
-
Fra 72.000 til 18.000 aktier tilbagekøbt på ugebasis. Sommeren er over os

-
Godmorgen.

-
lahn...Jeg er klædt på til lejligheden. Det er altid en fest at være på PI.

-
Genmab/BMO: Hæver kursmålet med over 100 kr.
https://www.proinvestor.com/investornyt/855348/genmab-bmo-haever-kursmalet-med-over-100-kr -
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
